Please login to the form below

Not currently logged in

UK biotech Retrogenix appoints Matthew Britiz

He takes up role as North American business development director

Retrogenix UK biotech Matt BritzRetrogenix has appointed Matthew Britz to lead its North American business development activities.  

He joins the Manchester, UK-based biotech from US strategy consulting firm Health Advances, where he was an associate, prior to which held the post of director of business development at Envoy Therapeutics.  

He began his life sciences career at Amgen, before gaining big pharma experience from Merck & Co and then Pfizer, where he served as a senior research engineer, subsequently joining Acambis (now part of Sanofi Pasteur).  

Britz will be based at newly-opened Cambridge, US office of Retrogenix, which provides drug target screening services to global pharmaceutical clients, and tasked with supporting the company's US and Canadian growth.    

Dr Jim Freeth, managing director of Retrogenix, said: “Matt will be an excellent ambassador for Retrogenix, maintaining our strong relationships with existing clients, expanding our client base and exploring other potential market applications for the Retrogenix technology.

“Matt has first-hand experience of the challenges that our clients face in drug discovery and development, making him an incredibly valuable asset. We look forward to supporting him in this new role.”

23rd June 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...